DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for gastroduodenitis — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGastroduodenitis maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for gastroduodenitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Экспериментальная и клиническая гастроэнтерология · 2023 · 2 citations · open access
Clinical and diagnostic features of chronic gastroduodenitis in children depending on the constitution type
AbstractAims . The study of clinical and diagnostic features of the course of chronic gastroduodenitis in children, taking into account the types of constitution (somatotypes), the impact of these features on the course of the disease and the treatment. Materials and methods . We studied 250 patients with a diagnosis of “Chronic gastroduodenitis” aged 4 to 17 years, with morphological changes in the mucous membrane of the stomach and duodenum, corresponding to the criteria for gastroduodenitis, as well as contamination with the H. pylori bacterium. An assessment was made of the age, gender composition, types of constitution according to the classifi cation of M. V. Chernorutsky (based on the Pignet index). Clinical- anamnestic and laboratory- instrumental features of the course of chronic gastroduodenitis in one or another somatotype were noted. The analysis and assessment of the infl uence of the constitutional specifi city of the patient on the course of the disease and the results of treatment was carried out. Results and conclusion . It was revealed that the presence of an asthenic type of constitution predisposes to the frequent development of chronic gastroduodenitis in children, but a milder course with the development of superfi cial gastroduodenitis, in contrast to normosthenic and hypersthenic types, prone to the development of hypertrophic and erosive gastroduodenitis. It was noted that in asthenics and normosthenics, the success of eradication anti- Helicobacter therapy is signifi cantly higher than in hypersthenics.
Response to urbanization: Madrid and Barcelona, 1850-1930
Abstractthe 1-month post-eradication UBT was probable true negative in all of the evaluated cases, since 79 patients (98.75%) were also negative after 1 year. The Hp recurrence rate is very low (1.25%) in a 1-year period. The symptoms were relieved shortly after eradication therapy in the majority of patients with ulcer disease or erosive lesions. However, significantly smaller portion of the patients with gastroduodenitis became symptom-free. Only about one third of the treated patients remained symptom-free 1 year after the eradication.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
